Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665000 | 0.84 | CYP1A2 (0.44) | KDM4EALDH1A1LMNACYP1A2HPGD | |
| SCHEMBL18323596 | 0.76 | KDM4E (0.50) | KDM4EALDH1A1LMNACYP1A2HPGD | |
| SCHEMBL15907134 | 0.75 | AURKA (0.35) | KDM4EALDH1A1LMNACYP1A2HPGD | |
| SCHEMBL21848974 | 0.69 | KDM4E (0.39) | KDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL14030430 | 0.68 | MEN1 (0.47) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15907080 | 0.68 | KDM4E (0.60) | KDM4EMEN1KMT2A | |
| SCHEMBL9689111 | 0.68 | KDM4E (0.46) | KDM4ELMNAHPGDHSD17B10KMT2A | |
| SCHEMBL15907119 | 0.67 | DNMT1 (0.56) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL9691180 | 0.66 | HPGD (0.56) | KDM4EALDH1A1LMNACYP1A2HPGD | |
| SCHEMBL23102794 | 0.64 | GABRA1 (0.40) | KDM4EALDH1A1CYP1A2HPGDNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | KDM4E 2547/4885ALDH1A1 3414/4885LMNA 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.